Product Information
CYLTEZO(CF) PEN 40 MG/0.8 ML is a brand biologic product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $3202.7520 per EA under NDC 00597037597. Its NADAC has been published 80 times since Dec 18, 2024.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597037597
Classification
Brand Biologic
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761058On Market Since
7/1/2023
Price Statistics
The NADAC for CYLTEZO(CF) PEN 40 MG/0.8 ML has been published 80 times since Dec 18, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $3202.7520 per EA |
|---|---|
| All-time high | $3207.2150 (May 14, 2025) |
| All-time low | $3199.1892 (Feb 18, 2026) |
| 52-week high | $3204.6700 |
| 52-week low | $3199.1892 |
| Median price | $3202.7520 |
| Average price | $3202.5510 |
| Largest weekly change | +0.1% (Mar 19, 2025) |
| Weeks tracked | 80 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the adalimumab-adbm market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of CYLTEZO(CF) PEN 40 MG/0.8 ML?
The current National Average Drug Acquisition Cost (NADAC) for CYLTEZO(CF) PEN 40 MG/0.8 ML, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $3202.7520 per EA (NDC 00597037597), effective Jun 24, 2026.
How has the price of CYLTEZO(CF) PEN 40 MG/0.8 ML changed over time?
Over the history we have for it, the NADAC for CYLTEZO(CF) PEN 40 MG/0.8 ML has held within roughly two percent of its current level. It has been tracked across 80 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for CYLTEZO(CF) PEN 40 MG/0.8 ML?
Since Dec 18, 2024, the NADAC for CYLTEZO(CF) PEN 40 MG/0.8 ML has ranged from a low of $3199.1892 (Feb 18, 2026) to a high of $3207.2150 (May 14, 2025), with a median of $3202.7520 per EA.
Are there cheaper alternatives to CYLTEZO(CF) PEN 40 MG/0.8 ML?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of CYLTEZO(CF) PEN 40 MG/0.8 ML, so no direct lower-cost alternative is listed.
Who manufactures CYLTEZO(CF) PEN 40 MG/0.8 ML?
CYLTEZO(CF) PEN 40 MG/0.8 ML (NDC 00597037597) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand biologic product.
Related Drugs
Same classification